Explore the latest in pharmocogenetics, including advances in personalized medicine from genetic markers of drug efficacy and adverse effects.
This study examines the frequency of drug patent invalidations based on inequitable conduct.
This genetic association study including genome-wide association study summary statistics of US and European adults uses mendelian randomization analysis to examine the association of genetic proxies of thiazide diuretics with the risk of kidney stones.
This Viewpoint discusses whether routine vaccination is safe for children with MT-RNR1 gene variants that predispose to aminoglycoside-induced hearing loss.
This cohort study investigates the association between lower birth weight and neurodevelopmental difficulties, as well as the causal association of intrauterine growth with measures of offspring neurodevelopmental difficulties.
This randomized clinical trial evaluates the clinical effectiveness of multigenetic pharmacogenomics–guided treatment in schizophrenia among Han men in China.
This prespecified subgroup analysis of the randomized clinical CHANCE-2 trial investigates whether the efficacy and safety of ticagrelor-aspirin vs clopidogrel-aspirin are consistent with the expected degree of CYP2C19 loss-of-function after transient ischemic attack or minor stroke.
This randomized clinical trial examines whether tricyclic antidepressant (TCA) dosing based on pharmacogenetics according to the Dutch Pharmacogenetics Working Group guidelines results in faster attainment of therapeutic TCA plasma concentrations compared with usual treatment.
This Viewpoint discusses the findings of the Clarity AD trial, which studied lecanemab for patients with early-stage Alzheimer disease.
This secondary analysis of a randomized clinical trial assesses whether GC gene missense variants encoding common vitamin D–binding protein isoforms modify the effects of vitamin D3 and/or calcium supplementation on colorectal adenoma recurrence risk.
This case-control study pools and analyzes individual-level data from 8 Ovarian Cancer Association Consortium case-control studies to evaluate whether a polygenic score modifies the association of frequent aspirin use with ovarian cancer.
This cohort study examines the use of targeted therapies, including epithelial growth factor receptor inhibitors and vascular endothelial growth factor inhibitors, in the treatment of patients with metastatic colorectal cancer.
This genetic association study replicated previously identified genetic factors and assessed novel genetic factors associated with hepatic toxic effects during treatment in pediatric patients with acute lymphoblastic leukemia (ALL).
This case report describes 2 patients with iatrogenic amyloidosis secondary to subcutaneous injections of anakinra to manage neonatal-onset multisystem inflammatory disease.
This cohort study uses data from the Taiwan National Health Insurance Research Database to assess whether prenatal benzodiazepine exposure was associated with development of autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD).
This prognostic study of the Cancer and Aging Research Group prediction model for chemotherapy-related toxic effects assesses the accuracy of this tool for older Asian adults.
This cohort study examines data for participants in the UK Biobank to determine associations of a combined reduction of CETP and PCSK9 concentrations with plasma lipid levels and such clinical outcomes as risk of coronary artery disease and age-related macula degeneration.
This secondary analysis of the Ticagrelor or Clopidogrel With Aspirin in High-risk Patients With Acute Nondisabling Cerebrovascular Events II (CHANCE-2) randomized clinical trial evaluates the time course for benefits and risks with ticagrelor and aspirin after minor stroke or transient ischemic attack in individuals who carry CYP2C19 loss-of-function alleles.
This randomized clinical trial compares the efficacy of treatment guided by pharmacogenomic testing vs usual care to determine whether pharmacogenomic testing affects antidepressant medication selection and whether such testing leads to better clinical outcomes among patients with major depressive disorder (MDD).
Customize your JAMA Network experience by selecting one or more topics from the list below.